Ergot Use and Overuse: A Pharmacoepidemiology Retrospective Cohort Study.

摘要: Objective The objective of this study was to estimate and characterize the actual patterns ergot use overuse in France using a drug reimbursement database. Methods We included all people covered by French General Health Insurance System (GHIS) from Provence-Alpes-Cote-d'Azur (PACA) Corsica administrative areas who had at least one prescription between May 2010 December 2011. All prescriptions ergots, migraine prophylactic treatment, psychotropic medications were extracted GHIS database. We defined occasional users ( 3 months prescription). Among regular users, we identified overusers nonoverusers. Results We 4358 patients ergots (oral ergotamine tartrate, dihydroergotamine mesilate nasal spray, intravenous mesilate). overusers, large majority tartrate overuse. The proportion is maximum after 55 years. Compared with more frequently treatment (93/165 [56.4%] versus 398/1057, OR = 2.15, P < .001), antidepressants (72/165 [43.6%] 326/1057 [30.8%] OR = 1.79, benzodiazepines (111/165 [67.3%] 613/1057 [58.0%], OR = 1.50, weak opioids (95/165 [57.6%] 463/1057 [43.8], OR = 1.77, P < .001) strong (13/165 [7.9%] 24/1057 [2.3%], OR = 3.86, P < .001). coexistence consumption triptan overuse, possibility both described; described than nonoverusers. Conclusions This work outlines high prevalence (11.1%). As are mostly aged years, an evaluation cardiovascular risk profile necessary elderly population.